Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of immunotherapy

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CJI.0b013e3182a80237PMID 23994887PMCID PMC3846277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.

  2013cited by this paper
• Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

  2012cited by this paper
• Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Immune response of 23‐valent pneumococcal polysaccharide vaccinated elderly and its relation to frailty indices, nutritional status, and serum zinc levels

  2012cited by this paper
• Trial Watch

  2012cited by this paper
• Trial watch

  2012cited by this paper
• CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model

  2011cited by this paper
• Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

  2011cited by this paper
• Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

  2011cited by this paper
• Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.

  2010cited by this paper
• WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

  2010cited by this paper
• GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

  2010cited by this paper
• Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

  2009cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

  2008cited by this paper
• New response criteria proposed for immunotherapies.

  2008cited by this paper
• Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

  2008cited by this paper
• Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients

  2008cited by this paper
• A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease

  2007cited by this paper
• Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21

  2007cited by this paper
• Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

  2007cited by this paper
• Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes

  2007cited by this paper
• Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy

  2007cited by this paper
• 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients

  2007cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

  2006cited by this paper
• Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer

  2006cited by this paper
• Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)

  2006cited by this paper
• Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma

  2006cited by this paper
• Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables

  2005cited by this paper
• A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.

  2005cited by this paper
• The bone marrow: a nest for migratory memory T cells.

  2005cited by this paper
• Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.

  2004cited by this paper
• High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells

  2004cited by this paper
• Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

  2004cited by this paper
• Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.

  2003cited by this paper
• Differences in T‐cell immunity toward tumor‐associated antigens in colorectal cancer and breast cancer patients

  2003cited by this paper
• All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Vaccinating patients with autologous tumor.

  2002cited by this paper
• Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.

  2001cited by this paper
• Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor Vaccine

  2000cited by this paper
• Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC1

  2000cited by this paper
• Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.

  2000cited by this paper
• Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

  2000cited by this paper
• Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response

  1999cited by this paper
• A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines

  1999cited by this paper
• Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study.

  1998cited by this paper
• NCI‐navy medical oncology branch cell line data base

  1996cited by this paper
• Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

  1996cited by this paper
• A simulation study of the number of events per variable in logistic regression analysis.

  1996cited by this paper
• Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

  1996cited by this paper
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

  1994cited by this paper
• Distinct effects of interferon-gamma and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis.

  1990cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Multiple Comparisons among Means

  1961cited by this paper

• Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective

  2025cites this paper
• Current Development of Therapeutic Vaccines in Lung Cancer

  2025cites this paper
• Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

  2024cites this paper
• Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis

  2024cites this paper
• Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

  2024cites this paper
• Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response

  2022cites this paper
• Potential association factors for developing effective peptide-based cancer vaccines

  2022cites this paper
• Utilizing chemokines in cancer immunotherapy.

  2022cites this paper
• Oncolytic Vaccinia Virus in Lung Cancer Vaccines

  2022cites this paper
• The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

  2021cites this paper
• Genomic analysis of the prognostic value of colony-stimulating factors (CSFs) and colony-stimulating factor receptors (CSFRs) across 24 solid cancer types

  2020cites this paper
• JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

  2020cites this paper
• Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting

  2020cites this paper
• Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

  2020cites this paper
• Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: What we know and future landscape

  2019influential citation
• FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

  2019cites this paper
• Prospects of Gene Therapy to Treat Melanoma

  2018cites this paper
• A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma

  2018cites this paper
• Vaccine and immune cell therapy in non-small cell lung cancer.

  2018cites this paper
• SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes

  2018cites this paper
• Immunotherapy in Lung Cancer.

  2017cites this paper
• Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

  2017cites this paper
• Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma

  2016cites this paper
• Experimental models of pediatric brain tumors. Establishment, immunophenotyping and clinical implications.

  2016cites this paper
• Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer.

  2016cites this paper
• Hematopoietic Cancer Cell Lines Can Support Replication of Sabin Poliovirus Type 1

  2015cites this paper
• Retinoid Chemoprevention: Who Can Benefit?

  2015cites this paper
• Hidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathways

  2015cites this paper
• A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model

  2015cites this paper
• Vaccine immunotherapy in lung cancer: Clinical experience and future directions.

  2015cites this paper
• Hidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathways

  2015cites this paper
• Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts

  2014cites this paper